Adjuvant Whole-Brain Radiotherapy After Radiosurgery or Surgical Resection of 1-3 Cerebral Metastases? Results of the EORTC 22952-26001 Study

被引：0
|
作者：
Nevinny-Stickel, Meinhard
机构：
来源：
STRAHLENTHERAPIE UND ONKOLOGIE | 2011年 / 187卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：332 / 333
页数：2
相关论文
共 50 条
  • [21] Survival Impact of Postoperative Whole-brain Radiotherapy and Systemic Chemotherapy After Surgical Resection of Brain Metastases
    Yoshioka, Hiromasa
    Okuda, Takeshi
    Fujita, Mitsugu
    Nakao, Takayuki
    Takahashi, Jun C.
    ANTICANCER RESEARCH, 2024, 44 (08) : 3663 - 3667
  • [22] Outcomes of adjuvant whole-brain radiotherapy versus hypofractionated stereotactic radiotherapy after surgical resection of brain metastases: a propensity score-matched analysis
    Keller, Audrey
    Lefebvre, Francois
    Ricard, Damien
    Noel, Georges
    Antoni, Delphine
    CHINESE CLINICAL ONCOLOGY, 2020, 9 (04)
  • [23] Stereotactic radiosurgery as therapy for melanoma, renal carcinoma, and sarcoma brain metastases: Impact of added surgical resection and whole-brain radiotherapy
    Rao, Ganesh
    Klimo, Paul, Jr.
    Thompson, Clinton J.
    Samlowski, Wolfram
    Wang, Michael
    Watson, Gordon
    Shrieve, Dennis
    Jensen, Randy L.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 66 (04): : S20 - S25
  • [24] Cost Analysis of Adjuvant Whole-Brain Radiotherapy Treatment Versus No Whole-Brain Radiotherapy After Stereotactic Radiosurgery and/or Surgery Among Adults with One to Three Melanoma Brain Metastases: Results from a Randomized Trial
    Anh Dam Tran
    Angela M. Hong
    Mai T. H. Nguyen
    Gerald Fogarty
    Victoria Steel
    Elizabeth Paton
    Rachael L. Morton
    PharmacoEconomics - Open, 2022, 6 : 587 - 594
  • [25] Cost Analysis of Adjuvant Whole-Brain Radiotherapy Treatment Versus No Whole-Brain Radiotherapy After Stereotactic Radiosurgery and/or Surgery Among Adults with One to Three Melanoma Brain Metastases: Results from a Randomized Trial
    Anh Dam Tran
    Hong, Angela M.
    Nguyen, Mai T. H.
    Fogarty, Gerald
    Steel, Victoria
    Paton, Elizabeth
    Morton, Rachael L.
    PHARMACOECONOMICS-OPEN, 2022, 6 (04) : 587 - 594
  • [26] Pre-Treatment Seizures in Patients With 1-3 Cerebral Metastases Receiving Local Therapies Plus Whole-brain Radiotherapy
    Witteler, Jaspar
    Kjaer, Troels W.
    Tvilsted, Soeren
    Schild, Steven E.
    Rades, Dirk
    IN VIVO, 2020, 34 (05): : 2727 - 2731
  • [27] Whole-Brain Radiotherapy vs. Localized Radiotherapy after Resection of Brain Metastases in the Era of Targeted Therapy: A Retrospective Study
    Koo, Jaho
    Roh, Tae Hoon
    Lee, Sang Ryul
    Heo, Jaesung
    Oh, Young-Taek
    Kim, Se-Hyuk
    CANCERS, 2021, 13 (18)
  • [28] Identifying Melanoma Patients with 1-3 Brain Metastases Who May Benefit from Whole-brain Irradiation in Addition to Radiosurgery
    Huttenlocher, Stefan
    Sehmisch, Lena
    Schild, Steven E.
    Blank, Oliver
    Hornung, Dagmar
    Rades, Dirk
    ANTICANCER RESEARCH, 2014, 34 (10) : 5589 - 5592
  • [29] Whole-brain radiotherapy versus stereotactic radiosurgery for patients in recursive partitioning analysis classes 1 and 2 with 1 to 3 brain metastases
    Rades, Dirk
    Pluemer, Andre
    Veninga, Theo
    Hanssens, Patrick
    Dunst, Juergen
    Schild, Steven E.
    CANCER, 2007, 110 (10) : 2285 - 2292
  • [30] A European Organisation for Research and Treatment of Cancer Phase III Trial of Adjuvant Whole-Brain Radiotherapy Versus Observation in Patients With One to Three Brain Metastases From Solid Tumors After Surgical Resection or Radiosurgery: Quality-of-Life Results
    Soffietti, Riccardo
    Kocher, Martin
    Abacioglu, Ufuk M.
    Villa, Salvador
    Fauchon, Francois
    Baumert, Brigitta G.
    Fariselli, Laura
    Tzuk-Shina, Tzahala
    Kortmann, Rolf-Dieter
    Carrie, Christian
    Ben Hassel, Mohamed
    Kouri, Mauri
    Valeinis, Egils
    van den Berge, Dirk
    Mueller, Rolf-Peter
    Tridello, Gloria
    Collette, Laurence
    Bottomley, Andrew
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (01) : 65 - 72
12345